CNTA

NEUTRALM&A

Centessa Pharmaceuticals plc

2026-06-02

Price

$39.90

+0.10%

Score14.5Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

Centessa Pharmaceuticals (CNTA) is trading in a highly controlled, low-volatility pattern driven entirely by Eli Lilly's pending acquisition for $38.00 in cash plus a $9.00 Contingent Value Right (CVR). The stock's current price of $39.90 reflects the market pricing in a solid probability of the CVR payout, which perfectly explains the QUIET_STORM and STEADY_CLIMB signals capturing this artificially compressed 1.8% realized volatility. While the broader RISK_ON macro regime is currently lifting small caps, CNTA's high-conviction price discovery is idiosyncratic, functioning as an institutional merger arbitrage play shielded from broader market beta.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONSELLER FATIGUE

Key Takeaways

M&A Arbitrage Dynamics: CNTA is trading at $39.90, well above the $38.00 cash buyout price, signaling strong institutional confidence in the realization of the $9.00 CVR [1.2.6].
Signal Confirmation: The presence of QUIET_STORM and STEADY_CLIMB signals perfectly aligns with the suppressed volatility and steady accumulation typical of a pending acquisition.
Key Risk & Watch Item: The primary risk is regulatory intervention or failure to meet CVR milestones; watch the $38.00 cash floor as the ultimate downside support.

← Back to 2026-06-02 View Full CNTA History →Yahoo Finance &nearr;